Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jueckstock J, Kurt A, Vilsmaier T, De Gregorio A, De Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann M, Fasching P, Janni W, Mueller V (2017)
Publication Type: Journal article
Publication year: 2017
Book Volume: 35
Pages Range: 130-135
DOI: 10.1016/j.breast.2017.07.007
BACKGROUND: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited. Anti-Müllerian hormone (AMH) known for ovarian reserve in reproductive medicine could be a surrogate marker and was assessed in premenopausal breast cancer patients of the SUCCESS A study (EUDRA-CT no. 2005-000490-21). METHODS: We identified 170 premenopausal patients, age ≤ 40 years at trial entry, who received FEC-Doc as taxane-anthracylince based chemotherapy. Blood samples were taken at three time points: Before, four weeks after and two years after adjuvant chemotherapy. Serum AMH-levels were evaluated in a central laboratory by a quantitative immunoassay AMH Gen II ELISA (Beckman Coulter, Brea, USA). RESULTS: Median age was 36 years (21-40 years). Median serum AMH-level before chemotherapy was 1.37 ng/ml (range < 0.1-11.3 ng/ml). Four weeks after chemotherapy AMH-levels dropped in 98.6% of the patients to <0.1 ng/ml (range < 0.1-0.21 ng/ml). After two years, 73.3% (n = 101) showed no evidence of ovarian function recovery (AMH <0.1 ng/ml, range < 0.1-3.9 ng/ml). Permanent chemotherapy induced amenorrhea occurred only in 50.6% of the patients. CONCLUSIONS: In this analysis, premenopausal patients showed a high rate of ovarian impairment reflected by low AMH-levels after chemotherapy.
APA:
Trapp, E., Steidl, J., Rack, B., Kupka, M.S., Andergassen, U., Jueckstock, J.,... Mueller, V. (2017). Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. BREAST , 35, 130-135. https://doi.org/10.1016/j.breast.2017.07.007
MLA:
Trapp, Elisabeth, et al. "Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study." BREAST 35 (2017): 130-135.
BibTeX: Download